AUTHORS
Juliana Xavier-Ferrucio, PhD, Sanhita Sengupta2, Nicholas Stong, PhD3, Michael Amatangelo, PhD4, Marija Bosilkovska Weisskopf, PhD5, Juliane Morando, MD6, Paulo Maciag, MD7, Paula Rodriguez Otero, MD, PhD8, Jesús G. Berdeja, MD9, Paul G. Richardson, MD10, Niels van de Donk, MD, PhD11, Chang-Ki Min, MD, PhD12, Hang Quach, MBBS MD FRACP FRCPA13, Kihyun Kim, MD, PhD14, Maria Gavriatopoulou, MD15, Meletios-Athanasios (Thanos) C. Dimopoulos, MD16, Anita Gandhi, PhD17, Sagar Lonial, MD, FACP18
AFFILIATIONS
1 Bristol Myers Squibb, Cambridge, United States
2 Bristol Myers Squibb, Madison, United States
3 Bristol Myers Squibb, Madison, United States
4 Bristol Myers Squibb, Madison, United States
5 Bristol Myers Squibb, Boudry, Switzerland
6 Bristol Myers Squibb, Madison, United States
7 Bristol Myers Squibb, Madison, United States
8 Clínica Universidad de Navarra, CIMA, IDISNA, CIBERONC, Pamplona, Spain
9 Tennessee Oncology, Nashville, United States
10 Dana-Farber Cancer Institute, Boston, United States
11 Department of Hematology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, Netherlands
12 Department of Internal Medicine, College of Medicine, Division of Hematology, Seoul St. Mary’s Hospital, Seoul,, Korea, Rep. of South
13 Department of Haematology, St Vincent’s Hospital, University of Melbourne, Melbourne, Australia
14 Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Rep. of South
15 Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece
16 Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece
17 Bristol Myers Squibb, Madison, United States
18 Winship Cancer Institute, Emory University,, Atlanta, United States
ABSTRACT
Iberdomide is a cereblon (CRBN)-modulating protein degrader that promotes Ikaros and Aiolos degradation, resulting in direct anti-myeloma activity and enhanced T- and NK-cell function.
In the randomized phase 3 EXCALIBER RRMM study, iberdomide, daratumumab, and dexamethasone (IberDd) significantly improved MRD-negative complete response (CR) rates versus daratumumab, bortezomib, and dexamethasone (DVd) in patients with RRMM after 1–2 prior lines of therapy. We evaluated associations between CRBN expression, genomic alterations, and immune characteristics with MRD-negative CR. MRD was assessed by next-generation flow; CRBN by dual CD138/CRBN immunohistochemistry; whole-genome sequencing and RNA sequencing on CD138+ bone marrow plasma cells; and peripheral blood immune populations by flow cytometry.
Baseline tumor-cell CRBN expression was not associated with MRD-negative CR in either arm. CRBN levels were comparable between responders and non-responders, irrespective of lenalidomide refractoriness in the most recent regimen (all p>0.05). MRD-negative CR occurred across the full range of CRBN expression, including low baseline CRBN in the IberDd arm. These findings suggest that low baseline CRBN does not identify a population that preferentially benefits from DVd over IberDd and that neither low CRBN nor lenalidomide refractoriness precluded MRD-negative CR with IberDd.
No statistically significant genomic predictors of MRD-negative CR were identified. Baseline CRBN dysregulation was present in 50% of IberDd-treated and 45% of DVd-treated patients, including loss of COPS7b, loss of COPS8, high CRBN-del-exon10 expression, or CRBN mutation, with no association with response. Although exploratory and limited by small numbers, MRD-negative CR was observed with IberDd but not DVd across multiple adverse-risk genomic subgroups, including amp1q (50%[2/4] vs 0%[0/5]), del17p (11%[1/9] vs 0%[0/4]), del1p (20%[1/5] vs 0%[0/1]), NRAS mutations (40%[2/5] vs 0%[0/5]), KMT2C mutations (40%[2/5] vs 0%[0/3]), KRAS mutations (33%[1/3] vs 22%[2/9]), and BRAF mutations (33%[1/3] vs 0%[0/4]), suggesting the MRD benefit of IberDd extends across adverse-risk genomic subgroups.
Baseline immune cell counts and frequencies were comparable between the IberDd (n=170) and DVd (n=159) arms, but immune associations with sustained MRD-negative CR differed by treatment. In IberDd-treated patients, sustained MRD-negative CR for ≥6 months was associated with greater baseline abundance of mature NK cells, including higher CD57+ NK-cell frequency (IberDd: p=0.0036 vs. DVd: p=0.507), higher differentiated/activated CD57+CD366+ NK-cell counts (IberDd: p= 0.0278 vs. DVd: p=0.13), higher frequencies of cytotoxic CD56midCD16+ NK cells (IberDd: p= 0.0183 vs. DVd: p= 0.603), and lower baseline proliferation (Ki67+) of mature NK cells (IberDd: p= 0.0129 vs. DVd p= 0.416), consistent with a larger, more differentiated NK-cell compartment rather than pre-existing immune activation. At C1D8, sustained MRD-negative CR correlated with early increases in proliferating NK-cell subsets and CD4/CD8 T-cell populations (p≤0.05), suggesting treatment-induced NK/T-cell activation may contribute to MRD response durability. In contrast, immune correlates of MRD durability in the DVd arm were fewer at baseline and more heterogeneous on treatment.
Together, these findings suggest that durable MRD negativity with IberDd is associated with a coordinated baseline NK-cell fitness profile and early treatment-induced immune activation, supporting an immune-mediated mechanism of response that is more pronounced with IberDd than with DVd.
Deep and durable MRD-negative responses with IberDd were observed across the full range of baseline CRBN expression and in multiple adverse-risk genomic subsets. Sustained MRD negativity in the IberDd arm was associated with a mature NK-cell–enriched baseline immune profile and early on-treatment NK- and T-cell activation despite similar baseline NK-cell distributions across treatment arms. Together, this supports an immune-mediated mechanism underlying the superior MRD outcomes observed with IberDd and suggest that baseline NK-cell fitness, coupled with iberdomide-driven immune remodeling and early NK/T-cell activation, contributes to the development of durable MRD negativity. These findings suggest that use of IberDd earlier in disease course, when NK-cell fitness is more likely preserved, may enhance MRD response depth and durability.
DISCLOSURES
Juliana Xavier-Ferrucio, PhD: BMS - Current equity holder in publicly-traded company; VOR - Ended employment in the past 24 months; BMS - Current Employment